As such, immune-checkpoint inhibitors targeting TIGIT and TIM3 are interesting molecular targets to induce more potent NK cell engagement against CML cells, but further studies are needed with larger cohort of primary CML cells. The gene discussed is HAVCR2; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.